| Outcome Measures: |
Primary: Changes of HbA1c level, Patients achieving the target level, baseline, week 12, week 24|Changes of CAP score, Controlled Attenuation Parameter (CAP) score by transient elastography, baseline, week 24 | Secondary: Changes of LSM score, Liver stiffness measurement (LSM) score by transient elastography, baseline, week 24|Changes of noninvasive liver fibrosis markers, Noninvasive liver fibrosis markers will be calculated at baseline and at the end of the study, baseline, week 12, week 24|Changes of body weight and body composition, Body composition by bioelectrical impedance will be measured at baseline and at the end of the study, baseline, week 24|Changes of lipid levels, Cholesterol level will be measured at all visit days, baseline, week 12, week 24|Changes of ketone levels, Ketone level will be measured at all visit days, baseline, week 12, week 24|Changes of liver parenchyma by ultrasonography, improvement or deterioration, baseline, week 24|Changes of liver function parameters, Liver enzymes, albumin will be measured at all visit days., baseline, week 12, week 24|Changes of liver fibrosis biomarkers, Type IV collagen, baseline, week 24|Changes of inflammation biomarker, high-sensitivity CRP, baseline, week 24 | Other: Changes of urine markers, Urinalysis will be performed at all visit days, baseline, week 12, week 24|Changes of bone health, parathyroid hormone, 25-hydroxylated vitamin will be measured at all visit days, baseline, week 12, week 24|Changes of gut microbiota, gut microbiota composition, microbiota related to metabolic dysfunction, baseline, week 24
|
